Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Core Insights - Myriad Genetics has expanded its collaboration with Illumina to integrate their technologies, enhancing the capabilities of genomic profiling in cancer diagnostics [3][5] - The Genomic Instability Score (GIS) will now be included in all samples analyzed with Illumina's TruSight™ Oncology 500 v2 assay, broadening the range of cancer types that can receive HRD status [2][4] - This partnership aims to strengthen Myriad's oncology product portfolio and facilitate the development of companion diagnostics for HRD-based therapies across various tumor types [4][5] Company Overview - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on improving health outcomes through genetic insights [7] - The company offers tests that assess disease risk and guide treatment decisions, ultimately aiming to enhance patient care and reduce healthcare costs [7] Technology and Product Development - Myriad's MyChoice CDx is a comprehensive HRD test that identifies patients with tumors vulnerable to DNA-damaging drugs, utilizing advanced sequencing technologies [6] - The integration of GIS into Myriad's Precise Tumor clinical reports will enhance the utility of their genomic profiling tests [5]